Observational studyHematological oncology2026

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.